做人流哪个医院好昌吉(昌吉泌尿外科去哪家医院) (今日更新中)

As the NBA prepares to resume the 2020-21 season tomorrow, basketball commissioner Adam Silver told Good Morning America on Wednesday that the league would “cease completely” if an outbreak of the virus occurred within the league.Silver’s comments come as baseball’s Miami Marlins has had a number of its players and coaches test positive for the virus in recent days, forcing the team to suspend play for the week. Likewise, the Philadelphia Phillies, which played the Marlins last weekend, have suspended several games this week.“it’s not an exact science because nobody’s ever done this before,” Silver said. “I think we have plans in place where we might pause, similar to what baseball is doing now. Probably, if we had any significant spread is immediately stop. One thing we’d try do is try to track those cases to determine where they’re coming from and whether there had been spread on campus. Ultimately, I think we would cease completely if we saw that it was spreading around the campus and something more than an isolated case was happening."Unlike baseball, basketball has kept its players in a “bubble” in Orlando, Florida. Even though the virus is circulating through the state, the latest round of COVID-19 tests showed no players or coaches tested positive for the virus in Orlando.But that hasn’t stopped Silver from being anxious about the resumption of play. After all, it took just positive test, Utah Jazz star Rudy Gobert, to shut down the league back in March.“There is a high case rate in Florida down in Orange County, where Orlando is, as well obviously what is happening in baseball with the Marlins, so it is something we are keeping track of very closely,” Silver said. “We have confidence in this protocol that we designed… Everyone that is on that campus is tested on a daily basis.”The MLS and NHL have followed similar plans by isolating players. Both leagues have in recent days not reported any COVID-19 cases. The MLS had two teams withdraw from its mid-season tournament due to the spread of the virus, but has been virus free for two weeks. 2089

Authorities say a seventh grader who died by suicide inside a northeast Ohio middle school bathroom last week planned to carry out an attack on the school.According to Jackson Township Police Chief Mark Brink, the Jackson Memorial Middle School student admired the Columbine shooters and had an eight-step plan to carry out an attack.The boy "intended to conduct a school shooting and harm others," Brink said. On Feb. 20, police responded to Jackson Memorial Middle School in Stark County after receiving a call about a student who had shot himself in the boy's bathroom.According to the medical examiner's office, the boy died from a self-inflicted gunshot wound to the head.Security cameras captured the 13-year-old on video coming out of the restroom with a .22 caliber semi-automatic rifle he had brought to school under his clothes. The boy went back inside the restroom and shot himself, police said.Investigators said it doesn't appear the boy shared his plan with anyone else, and he did not really have a presence on social media.Case of 13-year-old boy who shot himself inside Jackson Memorial Middle School has been ruled a suicide, according to the Summit County Medical Examiner. Boy passed away at Akron Children’s Hospital. @WEWS pic.twitter.com/JmlDIeLwbR— Bob Jones WEWS (@bobjonesTV) March 1, 2018 1354

As states prepare to assist in distributing potential coronavirus vaccines by November 1, Surgeon General Jerome Adams doubted a vaccine would be ready so soon.Speaking to ABC’s Good Morning America, Adams said a Nov. 1 vaccine was “possible, but not probable.”Last week, the federal government asked states to be prepared to begin assisting in distribution of COVID-19 vaccines to the public this fall.The memo signed by CDC head Robert Redfield told governors that the federal government has contracted with the McKesson Corporation to assist in distributing the vaccine to local and state health departments, medical facilities, doctor officers, and other vaccine providers.So why is the government getting states ready for a vaccine on November 1 even if it’s unlikely a vaccine will be approved by then?"It's not contradictory information," Adams told Good Morning America. "We've always said that we're hopeful for a vaccine by the end of this year or the beginning of next year.""We want to make sure states are available to distribute it," he added.While there is urgency for both public health and economic reasons for a vaccine, some experts have expressed concern over the speed of a vaccine and whether the expedited timeline is long enough to demonstrate efficacy. Dr. Anthony Fauci told NBC News on Wednesday that he believes a “safe and effective” vaccine could be ready by the end of the year."I believe that by the time we get to the end of this calendar year, that we will feel comfortable that we do have a safe and effective vaccine," he told NBC News.On Monday, a third vaccine candidate entered “Phase 3” trials in the US. AstraZeneca is testing its COVID-19 vaccine candidate for 30,000 participants. The AstraZeneca vaccine would come in two separate doses, according to the National Institutes of Health.Even though a vaccine could be ready by year’s end, trials will be expected to continue for over a year to monitor for possible side effects.According to the FDA, a typical Phase 3 trial would take one to three years.“NIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,” said NIH Director Francis S. Collins, M.D., Ph.D. “We also know that preventing this disease could require multiple vaccines and we’re investing in those that we believe have the greatest potential for success.”On Friday, President Donald Trump reiterated that a vaccine would be ready soon."We have tremendous, tremendous talent, some tremendous scientists, and they're right there, and I think you're going to hear some very good news,” Trump said. 2714

As more and more public spaces open back up, many people are finding themselves a little jumpy when they hear someone cough nearby. Are they sick, is it allergies, is it coronavirus?Chances are, we are jumping to conclusions about those “sick” sounds we find disgusting, according to a recently published study from the University of Michigan and University of California, Irvine.“We find no evidence that perceivers can reliably detect pathogen threats from cough and sneeze sounds, even though they are reasonably certain they can,” said Nicholas Michalak, the study’s lead author and a University of Michigan psychology graduate student.In other words, we humans are not very good at distinguishing the seriousness of a cough or sniffle by the sound of it. In fact, the study found that the more disgusting a person perceived the sound to be, the more likely they were to believe the sound came from an infected person, regardless of whether it did.Previous research has indicated people can accurately diagnose infection in others using other senses, like sight and smell.The research is based on four studies that had participants judge whether a cough or sneeze sound came from people infected with a communicable (easily spread) disease or not. On average, participants guessed four out of ten sounds correctly.“Moreover, there was no evidence that accuracy improved when participants knew the true number of infectious sounds in advance or when participants focused on how clear or disgusting they perceived the sounds,” Michalak said. “Despite this poor overall accuracy, perceivers consistently reported reasonable certainty in their judgments.”The study’s authors theorized that people have a belief that a sound that disgusts them is likely to represent a disease threat - this could lead them to exhibit biases to avoid interactions with others who make disgusting but noninfectious noises, according to Mickalak.The study’s co-authors are Oliver Sng, assistant professor of psychological science at UC-Irvine, and U-M graduate student Iris Wang and U-M associate professor of psychology Joshua Ackerman.Read the full study here. 2150

As the world waits for deliveries of Pfizer’s coronavirus vaccine, the pharmaceutical company is having to adjust their target after hitting supply chain obstacles, according to the Wall Street Journal.“Scaling up the raw material supply chain took longer than expected,” a company spokeswoman told the WSJ.Pfizer and partner BioNTech SE had hoped to ship out 100 million doses of their vaccine by the end of the year, that has now reportedly been cut to estimates of about 50 million.Two doses are needed for each person to be vaccinated.Pfizer did not elaborate on where the raw material shortfalls happened. They did say some raw materials in early production earlier this year did not meet their standards and they had to fix the issue.After the WSJ’s report, Pfizer’s stock price dropped and the S&P 500 fell slightly.The United Kingdom has granted emergency use of the Pfizer vaccine, and is expected to start administering doses soon. The FDA in the U.S. is considering a similar authorization, which could come later in December.As part of Operation Warp Speed, the U.S. Government has purchased 100 million doses of Pfizer’s vaccine, with an option to buy more.Roughly 20 million of those doses were expected by the end of the year once the FDA granted emergency use authorization. No word on how Pfizer’s shipping delays could impact this number.Pfizer says their production lines in the U.S. and Europe are complete and they are “confident” they will supply the targeted number of doses in early 2021. 1524

来源：资阳报